Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma
Status:
Recruiting
Trial end date:
2023-06-14
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well binimetinib and imatinib work in treating patients with
stage III-IV KIT-mutant melanoma that cannot be removed by surgery (unresectable).
Binimetinib and imatinib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth. Giving binimetinib and imatinib may help treat patients with
KIT-mutant melanoma.